The statistical analysis shows that there is a significant difference between resmetirom and placebo in NASH Biomarkers at 52 weeks which favors resmetirom group for CK-18/M30, Reverse T3 and favors placebo group for Adiponectin. The gene discussed is ADIPOQ; the disease is metabolic dysfunction-associated steatohepatitis.